Selected article for: "acute ARDS respiratory distress syndrome patient and ARDS respiratory distress syndrome"
Author: McCreary, Erin K; Pogue, Jason M
Title: Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
  • Document date: 2020_3_23
    • ID: j0i9ozsz_20
    Snippet: Based on in vitro findings, Chu et al [23] utilized combination therapy with LPV/r, ribavirin, and corticosteroids for any newly diagnosed patient with SARS-CoV-1 without acute respiratory distress syndrome (ARDS) starting in April 2003. Patients receiving LPV/r combination therapy (N = 41) were matched to historical patients receiving ribavirin plus corticosteroids (N = 111), and a significant reduction in the development of ARDS or death at 21 .....
    Document: Based on in vitro findings, Chu et al [23] utilized combination therapy with LPV/r, ribavirin, and corticosteroids for any newly diagnosed patient with SARS-CoV-1 without acute respiratory distress syndrome (ARDS) starting in April 2003. Patients receiving LPV/r combination therapy (N = 41) were matched to historical patients receiving ribavirin plus corticosteroids (N = 111), and a significant reduction in the development of ARDS or death at 21 days was observed (2.4% vs 28.8%, P < .001). This was corroborated by an expanded case-control matched study of 75 LPV/r-treated patients from the same center that demonstrated a significant reduction in pulse steroid use (27.3% vs 55.4%), intubation (0% vs 11%), and mortality (2.3% vs 15.6%) among patients who received LPV/r combination versus no LPV/r, respectively, as initial therapy [28] . More important, the benefits of LPV/r were only demonstrated in patients who received initial treatment with LPV/r (defined as initiation of drug at time of SARS-CoV-1 diagnosis). There was no observed benefit when LPV/r was added as rescue or salvage therapy (death rate 12.9% vs 14%).

    Search related documents:
    Co phrase search for related documents
    • acute ARDS respiratory distress syndrome and case control: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acute ARDS respiratory distress syndrome and combination therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute ARDS respiratory distress syndrome and death ARDS development: 1, 2, 3
    • acute ARDS respiratory distress syndrome and death rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute ARDS respiratory distress syndrome and distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ARDS respiratory distress syndrome and historical patient: 1
    • acute ARDS respiratory distress syndrome and initial therapy: 1, 2, 3
    • acute ARDS respiratory distress syndrome and initial treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • ARDS respiratory distress syndrome and case control: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • ARDS respiratory distress syndrome and combination therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • ARDS respiratory distress syndrome and death ARDS development: 1, 2, 3
    • ARDS respiratory distress syndrome and death rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • ARDS respiratory distress syndrome and distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ARDS respiratory distress syndrome and historical patient: 1
    • ARDS respiratory distress syndrome and initial therapy: 1, 2, 3, 4
    • ARDS respiratory distress syndrome and initial treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • case control and combination therapy: 1, 2, 3, 4, 5
    • case control and death rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • case control and distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25